Integrating Genomic Testing for Melanoma Into Your Practice

Main Article Content

Nicholas Brownstone
Danny Zakria
McKenzie Dirr
Yenn Lu
Darrell Rigel

Keywords

melanoma, skin cancer, genetic testing, 31-GEP, 2-GEP, prognosis, diagnosis, pigmented lesion

Abstract

Abstract not available. 

References

1. Mossbacher U, Knollmayer S, Binder M, Steiner A, Wolff K, Pehamberger H. Increased nuclear volume in metastasizing “thick” melanomas. J Invest Dermatol. 1996;106(3):437-440. doi:10.1111/1523-1747.ep12343580

2. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg. 1970;172(5):902-908.

3. Morton DL, Thompson JF, Cochran AJ, et al. Final Trial Report of Sentinel-Node Biopsy versus Nodal Observation in Melanoma. N Engl J Med. 2014;370(7):599-609. doi:10.1056/NEJMoa1310460

4. More people die from thin melanomas than thick melanomas. Accessed December 13, 2021. https://www.mdedge.com/internalmedicine/article/87682/melanoma/more-people-die-thin-melanomas-thick-melanomas

5. Santillan AA, Messina JL, Marzban SS, Crespo G, Sondak VK, Zager JS. Pathology review of thin melanoma and melanoma in situ in a multidisciplinary melanoma clinic: impact on treatment decisions. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(3):481-486. doi:10.1200/JCO.2009.24.7734

6. Ferguson PM, Gershenwald JE, Scolyer RA. Staging of Cutaneous Melanoma: Is There Room for Further Improvement? JAMA Netw Open. 2018;1(1):e180086. doi:10.1001/jamanetworkopen.2018.0086

7. Puglisi R, Bellenghi M, Pontecorvi G, Pallante G, Carè A, Mattia G. Biomarkers for Diagnosis, Prognosis and Response to Immunotherapy in Melanoma. Cancers. 2021;13(12):2875. doi:10.3390/cancers13122875

8. Brouha B, Ferris L, Skelsey M, et al. Genomic Atypia to Enrich Melanoma Positivity in Biopsied Lesions: Gene Expression and Pathology Findings From a Large U.S. Registry Study. SKIN J Cutan Med. 2021;5(1):13-18. doi:10.25251/skin.5.1.3

9. Gerami P, Cook RW, Wilkinson J, et al. Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma. Clin Cancer Res Off J Am Assoc Cancer Res. 2015;21(1):175-183. doi:10.1158/1078-0432.CCR-13-3316

10. Gastman BR, Zager JS, Messina JL, et al. Performance of a 31-gene expression profile test in cutaneous melanomas of the head and neck. Head Neck. 2019;41(4):871-879. doi:10.1002/hed.25473

11. Mirsky R, Prado G, Svoboda R, Glazer A, Rigel D. Management Decisions Made by Physician Assistants and Nurse Practitioners in Cutaneous Malignant Melanoma Patients: Impact of a 31-Gene Expression Profile Test. J Drugs Dermatol JDD. 2018;17(11):1220-1223.

12. Keller J, Schwartz TL, Lizalek JM, et al. Prospective validation of the prognostic 31-gene expression profiling test in primary cutaneous melanoma. Cancer Med. 2019;8(5):2205-2212. doi:10.1002/cam4.2128

13. Dillon LD, Gadzia JE, Davidson RS, et al. Prospective, Multicenter Clinical Impact Evaluation of a 31-Gene Expression Profile Test for Management of Melanoma Patients. SKIN J Cutan Med. 2018;2(2):111-121. doi:10.25251/skin.2.2.3

14. Durham AB, Schwartz JL, Lowe L, et al. The natural history of thin melanoma and the utility of sentinel lymph node biopsy. J Surg Oncol. 2017;116(8):1185-1192. doi:10.1002/jso.24765

15. Schuitevoerder D, Heath M, Cook RW, et al. Impact of Gene Expression Profiling on Decision-Making in Clinically Node Negative Melanoma Patients after Surgical Staging. J Drugs Dermatol JDD. 2018;17(2):196-199.

16. Hsueh EC, DeBloom JR, Lee J, et al. Interim analysis of survival in a prospective, multi-center registry cohort of cutaneous melanoma tested with a prognostic 31-gene expression profile test. J Hematol OncolJ Hematol Oncol. 2017;10(1):152. doi:10.1186/s13045-017-0520-1

17. Vetto JT, Hsueh EC, Gastman BR, et al. Guidance of sentinel lymph node biopsy decisions in patients with T1-T2 melanoma using gene expression profiling. Future Oncol Lond Engl. 2019;15(11):1207-1217. doi:10.2217/fon-2018-0912

18. Vetto JT, Hsueh EC, Gastman BR, et al. Guidance of sentinel lymph node biopsy decisions in patients with T1-T2 melanoma using gene expression profiling. Future Oncol Lond Engl. 2019;15(11):1207-1217. doi:10.2217/fon-2018-0912

19. Gerami P, Yao Z, Polsky D, et al. Development and validation of a noninvasive 2-gene molecular assay for cutaneous melanoma. J Am Acad Dermatol. 2017;76(1):114-120.e2. doi:10.1016/j.jaad.2016.07.038

20. Skelsey M, Brouha B, Rock J, et al. Non-Invasive Detection of Genomic Atypia Increases Real-World NPV and PPV of the Melanoma Diagnostic Pathway and Reduces Biopsy Burden. SKIN J Cutan Med. 2021;5(5):512-523. doi:10.25251/skin.5.5.9

21. Ferris LK, Rigel DS, Siegel DM, et al. Impact on clinical practice of a non-invasive gene expression melanoma rule-out test: 12-month follow-up of negative test results and utility data from a large US registry study. Dermatol Online J. 2019;25(5):13030/qt61w6h7mn.

22. Elmore JG, Barnhill RL, Elder DE, et al. Pathologists’ diagnosis of invasive melanoma and melanocytic proliferations: observer accuracy and reproducibility study. BMJ. 2017;357:j2813. doi:10.1136/bmj.j2813

Most read articles by the same author(s)

1 2 > >>